Baselga J et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S3-3.

Belavic JM. Denosumab (Prolia): A new option in the treatment of osteoporosis. Nurse Pract 2011;36(1):11-2. No abstract available

Blowers E, Hall K. Adverse events in bevacizumab and chemotherapy: Patient management. Br J Nurs 2009;18(7):424-8. Abstract

Brem S, Kumar NB. Management of treatment-related symptoms in patients with breast cancer. Clin J Oncol Nurs 2011;15(1):63-71. Abstract

Frankel C, Palmieri FM. Lapatinib side-effect management. Clin J Oncol Nurs 2010;14(2):223-33. Abstract

Gianni L et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized Phase II study ('NeoSphere'). San Antonio Breast Cancer Symposium 2010;Abstract S3-2.

Hurtig J. Managing patients with advanced and metastatic breast cancer. Clin J Oncol Nurs 2010;14(3):313-23. Abstract

Mackey JR. Poster discussion: Metastatic breast cancer erbB/HER directed therapies. Breast Cancer Symposium 2009. Discussant.

Mayer M. Lessons learned from the metastatic breast cancer community. Semin Oncol Nurs 2010;26(3):195-202. Abstract

Montgomery M, McCrone SH. Psychological distress associated with the diagnostic phase for suspected breast cancer: Systematic review. J Adv Nurs 2010;66(11):2372-90. Abstract

Moss LS et al. Trastuzumab-induced cardiotoxicity. Oncol Nurs Forum 2009;36(6):676-85. Abstract

Onishi T et al. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 2010;7(11):641-51. Abstract

Palmieri FM et al. Adjuvant trastuzumab for HER2-positive early breast cancer. Clin J Oncol Nurs 2010;14(3):326-36. Abstract

Robertson FM et al. Inflammatory breast cancer: The disease, the biology, the treatment. CA Cancer J Clin 2010;60(6):351-75. Abstract

Rosedale M, Fu MR. Confronting the unexpected: Temporal, situational, and attributive dimensions of distressing symptom experience for breast cancer survivors. Oncol Nurs Forum 2010;37(1):E28-33. Abstract

Stopeck AT et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28(35):5132-9. Abstract

Untch M et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). San Antonio Breast Cancer Symposium 2010;Abstract S3-1.

Wilton JM. Denosumab: New Horizons in the treatment of osteoporosis. Nurs Womens Health 2011;15(3):249-52. No abstract available

ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study; BIG 2-06/N063D. NCT00490139

An open-label study of trastuzumab-MCC-DM1 (T-DM1) vs capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer (EMILIA). NCT00829166

Study of suitable schedule of docetaxel, anthracycline and cyclophosphamide in adjuvant therapy of breast cancer. NCT00525642